Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
Plan ensures shareholders are protected and treated equitably
Does not prevent the Zymeworks Board from engaging on future acquisition proposal that is in the best interests of all shareholders
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its board of directors (the "Board") has adopted a limited-duration shareholder rights plan (the "Rights Plan"). The Board adopted the Rights Plan in response to the unsolicited, non-binding proposal by All Blue Falcons FZE ("All Blue") to acquire Zymeworks and All Blue's continued share accumulations.
The Rights Plan is intended to enable all s
